Mylan Technologies Inc.

Quick facts

Phase 3 pipeline

• MR-100A-01 · Diabetes
  MR-100A-01 is a small molecule drug that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Mylan Technologies Inc. portfolio CI brief
• Mylan Technologies Inc. pipeline updates RSS